Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study
This study was designed to assess the effects of moxonidine on blood pressure and aspects of the metabolic syndrome in racially diverse population of patients encountered in routine medical practice. Physicians collected data on a minimum of three consecutive patients with uncontrolled essential hyp...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.1155/2013/541689 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849306702444232704 |
|---|---|
| author | Irina Chazova Markus P. Schlaich |
| author_facet | Irina Chazova Markus P. Schlaich |
| author_sort | Irina Chazova |
| collection | DOAJ |
| description | This study was designed to assess the effects of moxonidine on blood pressure and aspects of the metabolic syndrome in racially diverse population of patients encountered in routine medical practice. Physicians collected data on a minimum of three consecutive patients with uncontrolled essential hypertension and criteria for metabolic syndrome, eligible to receive moxonidine (0.2–0.4 mg once daily) for 6 months, either as monotherapy or as adjunct therapy to current antihypertensive treatment. Systolic and diastolic blood pressure (BP) declined by an average of 24.5+14.3 mmHg and 12.6+9.1 mmHg, respectively. BP responder rates defined as attaining BP < 140/90 mmHg were significantly (P<0.001) and substantially higher among younger patients, nonpostmenopausal women, and patients receiving monotherapy. While potentially relevant improvements in the entire cohort were observed in regard to body weight (-2.1±5.4 kg), fasting plasma glucose (from 6.8 to 6.2 mmol/L), and triglycerides (2.4 to 2.0 mmol/L), statistically significant changes in metabolic parameters could only be detected in subgroup analyses. Moxonidine therapy reduced blood pressure and improved rates of blood pressure control in this group of patients. While the observed trend towards improvement in various metabolic parameters merits further investigation, the overall effect of moxonidine treatment is consistent with a reduction of total cardiovascular risk in this hypertensive metabolic syndrome cohort. |
| format | Article |
| id | doaj-art-263434b0adf44f85846e5e0256c78d9d |
| institution | Kabale University |
| issn | 2090-0384 2090-0392 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-263434b0adf44f85846e5e0256c78d9d2025-08-20T03:55:00ZengWileyInternational Journal of Hypertension2090-03842090-03922013-01-01201310.1155/2013/541689541689Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY StudyIrina Chazova0Markus P. Schlaich1Clinical Cardiology Institute A.L. Myasnikov FSI Russian Cardiology Scientific and Production Complex Ministry of Health, 3rd Cherepkovskaya No. 15, Moscow 121552, RussiaNeurovascular Hypertension and Kidney Disease Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, VIC 8008, AustraliaThis study was designed to assess the effects of moxonidine on blood pressure and aspects of the metabolic syndrome in racially diverse population of patients encountered in routine medical practice. Physicians collected data on a minimum of three consecutive patients with uncontrolled essential hypertension and criteria for metabolic syndrome, eligible to receive moxonidine (0.2–0.4 mg once daily) for 6 months, either as monotherapy or as adjunct therapy to current antihypertensive treatment. Systolic and diastolic blood pressure (BP) declined by an average of 24.5+14.3 mmHg and 12.6+9.1 mmHg, respectively. BP responder rates defined as attaining BP < 140/90 mmHg were significantly (P<0.001) and substantially higher among younger patients, nonpostmenopausal women, and patients receiving monotherapy. While potentially relevant improvements in the entire cohort were observed in regard to body weight (-2.1±5.4 kg), fasting plasma glucose (from 6.8 to 6.2 mmol/L), and triglycerides (2.4 to 2.0 mmol/L), statistically significant changes in metabolic parameters could only be detected in subgroup analyses. Moxonidine therapy reduced blood pressure and improved rates of blood pressure control in this group of patients. While the observed trend towards improvement in various metabolic parameters merits further investigation, the overall effect of moxonidine treatment is consistent with a reduction of total cardiovascular risk in this hypertensive metabolic syndrome cohort.http://dx.doi.org/10.1155/2013/541689 |
| spellingShingle | Irina Chazova Markus P. Schlaich Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study International Journal of Hypertension |
| title | Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study |
| title_full | Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study |
| title_fullStr | Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study |
| title_full_unstemmed | Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study |
| title_short | Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study |
| title_sort | improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population principal results of the mersy study |
| url | http://dx.doi.org/10.1155/2013/541689 |
| work_keys_str_mv | AT irinachazova improvedhypertensioncontrolwiththeimidazolineagonistmoxonidineinamultinationalmetabolicsyndromepopulationprincipalresultsofthemersystudy AT markuspschlaich improvedhypertensioncontrolwiththeimidazolineagonistmoxonidineinamultinationalmetabolicsyndromepopulationprincipalresultsofthemersystudy |